Kythera Biopharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Much of the innovation in cosmetic dermatology has come from the multibillion-dollar, largely unregulated cosmeceuticals industry. But Kythera Biopharmaceuticals aims to bring true, rigorous clinical science to the field, with prescription drugs that modulate novel biological pathways in aesthetic and restorative indications.
You may also be interested in...
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.
Moving Beyond Accutane and Botox
Ever hungry for new investment opportunities, VCs are now backing start-ups developing novel dermatology products for both medical and cosmetic conditions. These aren't your typical "derm" companies. Not content to invent new delivery vectors for existing medicines or reformulate them into more patient friendly creams, these fledgling companies are trying to develop new chemical entities based on novel skin biology.